SCHEMBL9928200

SCHEMBL9928200

C#CC(O)(c1ccc(OC)cc1)c1ccc(OC)c(N2CCOCC2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
ALDH1A1 P00352 2/20 0.44
MAPT P10636 6/20 0.43
HSD17B10 Q99714 1/20 0.43
HTT P42858 4/20 0.41
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDM4E B2RXH2 1/20 0.40
PRKDC P78527 2/20 0.39
MAPK1 P28482 2/20 0.39
PAX8 Q06710 1/20 0.39
ADORA2A P29274 1/20 0.38
HPGD P15428 2/20 0.38
AKR1C3 P42330 1/20 0.38
NCOA1 Q15788 1/20 0.38
NCOA3 Q9Y6Q9 1/20 0.38
HTR1A P08908 1/20 0.38
HTR1D P28221 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13868731 0.94 AKR1C3 (0.41) MEN1KMT2AL3MBTL1ALDH1A1MAPT
SCHEMBL27165409 0.84 AKR1C3 (0.52) KMT2AL3MBTL1ALDH1A1MAPTHTT
SCHEMBL163753 0.84 AKR1C3 (0.52) KMT2AL3MBTL1ALDH1A1MAPTHTT
SCHEMBL25838223 0.82 MAPT (0.49) MEN1KMT2AALDH1A1MAPTHSD17B10
SCHEMBL9284349 0.82 ADORA2A (0.35) MEN1KMT2AL3MBTL1ALDH1A1MAPT
SCHEMBL28939782 0.81 MEN1 (0.45) MEN1KMT2AL3MBTL1ALDH1A1MAPT
SCHEMBL1816385 0.80 KMT2A (0.49) MEN1KMT2AALDH1A1MAPTHSD17B10
SCHEMBL30859290 0.80 MEN1 (0.43) MEN1KMT2AALDH1A1MAPTHSD17B10
SCHEMBL30859286 0.80 MEN1 (0.43) MEN1KMT2AALDH1A1MAPTHSD17B10
SCHEMBL27165401 0.80 MEN1 (0.43) MEN1KMT2AALDH1A1MAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8709308-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2014-04-29 US disclosed
US-8709308-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2014-04-29 US disclosed
US-8691120-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2014-04-08 US disclosed
US-8691120-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2014-04-08 US disclosed
US-20140034884-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2014-02-06 US disclosed
US-20140034884-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2014-02-06 US disclosed
US-20120270071-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2012-10-25 US disclosed
US-20120270071-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2012-10-25 US disclosed
US-20120170098-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2012-07-05 US disclosed
US-20120170098-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2012-07-05 US disclosed
US-20120161089-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2012-06-28 US disclosed
US-20120161089-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2012-06-28 US disclosed
US-20120145974-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2012-06-14 US disclosed
US-20120145974-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2012-06-14 US disclosed
US-7521004-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2009-04-21 US disclosed
US-7521004-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2009-04-21 US disclosed
US-20070215844-A1 Chromene Compound TOKUYAMA CORPORATION (JP) 2007-09-20 US disclosed
US-20070215844-A1 Chromene Compound TOKUYAMA CORPORATION (JP) 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120145974-A1 CHROMENE COMPOUND CRY2, CYP2J2, NR0B2 MEN1 2833/4885KMT2A 1418/4885L3MBTL1 3230/4885
US-20120170098-A1 CHROMENE COMPOUND CRY2, CRY1, SUN2 MEN1 1363/4885KMT2A 2494/4885L3MBTL1 3119/4885
US-20120270071-A1 CHROMENE COMPOUND NR0B2, NR2C2, NR0B1 MEN1 521/4885KMT2A 2211/4885L3MBTL1 4174/4885
US-20070215844-A1 Chromene Compound CRY2, TYR, CRY1 MEN1 925/4885KMT2A 411/4885L3MBTL1 3117/4885
US-20120161089-A1 CHROMENE COMPOUND CYP8B1, HSD3B2, CYP17A1 MEN1 401/4885KMT2A 2739/4885L3MBTL1 3570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.